FDA issues final guidance for assessing medical device safety, compatibility in MRI rooms

FDA issues final guidance for assessing medical device safety, compatibility in MRI rooms

FDA issues final guidance for assessing medical device safety, compatibility in MRI rooms Matt O’Connor | May 19, 2021 | Economics & Policy The U.S. Food & Drug Administration on Wednesday issued final guidance for assessing the safety and compatibility of medical devices within magnetic resonance imaging environments. The FDA said their recommendations apply to implanted devices, those fastened or carried by patients (external insulin pumps, pulse oximeter, etc.), and devices that may enter MRI rooms during clinical care, among many others. Its guidance does not, however, touch on MRI machines or components. “Ensuring safety and effectiveness for implants and other medical devices anticipated to enter the MR environment should be an integral part of medical device risk management,” the administration said in its May 19 statement. Additionally, the 32-page document outlines safety labeling information that should be included in premarket submissions along with key information to include in test report summaries and completed reports. “Appropriate testing and analyses, scientific rationale, and labeling, such as well-supported MR Conditional labeling…form the basis of adequate mitigations for the unique safety hazards of the MR environment,” the FDA said. Over the past few years, there have been a handful of non-medical devices to draw MRI warnings from imaging experts. Most recently, the FDA put out a notice cautioning patients to leave behind their face masks with metal parts before entering MRI rooms. The warning came after an individual reported facial burns consistent with the shape of a mask during their exam. Radiologists have also sounded the alarm against wearing magnetic eyelashes during such scans, which can ruin imaging quality and put patients at risk. You can read the entire “Testing and Labeling Medical Devices for Safety in the Magnetic Resonance  Environment” statement from the FDA here. Email this author Around the web AI IN HEALTHCARE Because they learn as they go, machine learning models for drug discovery have to be continuously re-trained for changing conditions in drug production processes. By Dave Pearson June 01 CARDIOVASCULAR BUSINESS PCI may be seen as a “reasonable alternative to CABG” for many elderly patients, the research team observed.  By Michael Walter June 01 RADIOLOGY BUSINESS The ABR has not yet determined whether remote testing will continue in 2023, a spokesman said. By Marty Stempniak May 28 RADIOLOGY BUSINESS Hyperpolarized xenon MRI enables sensitive, regional investigation of breathing and gas transfer into the blood stream, according to a new study in Radiology.  By Marty Stempniak May 28 RELATED ARTICLES ON ECONOMICS & POLICY

Read the full article at: www.healthimaging.com

Who We Are

Omnica Corporation is a privately-held design, engineering, and medical product development firm located in Irvine, California. The 28-person company is staffed with full-time employees and has been in operation since 1984. Our speciality is custom product development for the medical industry and industrial fields.

Our expertise is developing complex medical devices.Technical personnel at Omnica includes designers, mechanical engineers, electronic and software engineers, advanced R&D specialists, regulatory staff (for FDA documentation), machinists and model makers.

Learn MoreOmnica Corporation

Leave a Reply

Your email address will not be published. Required fields are marked *